146 related articles for article (PubMed ID: 35115315)
1. First Drug Approved for Rare Eye Cancer.
Cancer Discov; 2022 Apr; 12(4):879-880. PubMed ID: 35115315
[TBL] [Abstract][Full Text] [Related]
2. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
Liu AW; Wei AZ; Maniar AB; Carvajal RD
Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
[TBL] [Abstract][Full Text] [Related]
3. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract][Full Text] [Related]
4. Tebentafusp for the treatment of metastatic uveal melanoma.
Schank TE; Hassel JC
Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
[TBL] [Abstract][Full Text] [Related]
5. Tebentafusp: First Approval.
Dhillon S
Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
[TBL] [Abstract][Full Text] [Related]
7. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
[TBL] [Abstract][Full Text] [Related]
8. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights.
Rodriguez I; Norman T; Guenther J; Smart K; Kwong A; Berry J; In GK; Worswick S
Clin Exp Dermatol; 2024 Mar; 49(4):392-394. PubMed ID: 37956104
[No Abstract] [Full Text] [Related]
10. Tumor lysis syndrome induced by tebentafusp.
Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
[TBL] [Abstract][Full Text] [Related]
12. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence.
Lambertini M; Comito F; Melotti B; Baracca MF; Dika E
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e207-e208. PubMed ID: 36177547
[No Abstract] [Full Text] [Related]
15. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
Hua G; Carlson D; Starr JR
J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
[TBL] [Abstract][Full Text] [Related]
16. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
Damato BE; Dukes J; Goodall H; Carvajal RD
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704
[TBL] [Abstract][Full Text] [Related]
17. Selumetinib shows promise in metastatic uveal melanoma.
Cancer Discov; 2013 Jul; 3(7):OF8. PubMed ID: 23847383
[TBL] [Abstract][Full Text] [Related]
18. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
Komatsubara KM; Manson DK; Carvajal RD
Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
[TBL] [Abstract][Full Text] [Related]
19. FDA Approves Tebentafusp-Tebn For Unresectable Or Metastatic Uveal Melanoma.
Abbas Z; Wally HT; Qureshi FA
J Pak Med Assoc; 2023 Oct; 73(10):2127. PubMed ID: 37876091
[No Abstract] [Full Text] [Related]
20. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]